Tag: Lymphoma

  • New analysis sheds light on cancer incidence and mortality trends in the UK

    New analysis sheds light on cancer incidence and mortality trends in the UK

    [ad_1]

    In a recent study published in BMJ, researchers investigated trends in cancer incidence and deaths in the United Kingdom (UK) among individuals aged between 35 and 69 years.

    Study: 25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis. Image Credit: Image Point Fr/Shutterstock.comStudy: 25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis. Image Credit: Image Point Fr/Shutterstock.com

    Background

    Over the last 25 years, the UK has seen remarkable improvements in cancer risk factors, including a decline in smoking prevalence as a result of tariff rises, advertising restrictions, and smoke-free laws. Diet and exercise are leading to an increase in the number of overweight or obese individuals.

    Between 1993 and 2018, three screening programs for cervical, breast, and bowel cancer were implemented, with the ability to detect non-harmful cases. However, there is limited recent research on cancer incidences and deaths among those aged 35 to 69.

    About the study

    In the present study, researchers examined changes in cancer incidences and deaths in the United Kingdom between 1993 and 2018 for individuals aged 35 to 69 years.

    The researchers examined cancer registration, deaths, and nationwide population-level data from the Public Health Wales, Office for National Statistics (ONS), North Ireland Cancer Registry, Public Health Scotland, the General Register Office for North Ireland, and National Health Service (NHS) England.

    They investigated 23 cancer locations in the United Kingdom to determine cancer incidence and deaths among individuals aged 35 to 69 who received cancer diagnoses or died from cancers between 1993 and 2018.

    The team used the International Classification of Diseases, Tenth Revision (ICD-10) codes to diagnose cancers. The primary outcomes were changes in cancer incidences and deaths based on age across time.

    Sex-specific cancer groups were evaluated without breast and prostate cancers to examine general trends in the absence of the most prevalent cancer site for each gender.

    Mesothelioma was a new particular code released in ICD-10, and there were no credible mortality statistics available for this site before 2001; hence, the researchers did not include this kind of malignancy.

    They included non-malignant brain and spinal cord tumor codes, despite their benign character, because their presence in the cranial cavity can lead to death.

    The researchers omitted non-melanoma skin cancer from the incidence statistics due to incomplete documentation of these tumors, making the data unreliable. To account for yearly volatility in low-case sites, the researchers estimated three-year rolling average age-standardized rates per 100,000 population. They used generalized linear modeling for analysis.

    Results

    Cancer incidence among individuals aged 35 to 69 years increased by 57% (86,297 from 55,014) for males and 48% (88,970 from 60,187) for women, with an average yearly growth of 0.80% for both genders.

    Between 2003 and 2013, prostate and breast cancers grew in both sexes, with the male age-standardized incidence rate falling before 2000 and rising among women. Less frequent malignancies, such as melanoma, skin, liver, mouth, and kidney, have also shown alarming rises.

    For males aged 35 to 69 years, the highest mean yearly percentage elevations were for malignancies of hepatic tissues (4.70%), prostate (4.20%), and skin melanomas (4.20%). The highest yearly declines were for stomach (4.2%), bladder (4.10%), and lung (2.10%) cancers.

    For females, the highest average yearly percentage increases were for the liver (3.90%), skin melanomas (3.50%), and mouth (3.30%) cancers, whereas the highest annual declines were for bladder (3.60%) and stomach (3.10%).

    Over the past 25 years, cancer fatalities were reduced by 20% (26,322 from 32,878) in men and 17% (23,719 from 28,516) in women. Age-standardized mortality rates for all malignancies were decreased by 37% (2.0% each year) in men and 33% (1.6% per year) in women.

    The study discovered that after omitting prostate cancer from mortality trends, men’s death rates fell considerably, whereas women’s mortality decreased by 1.3% each year. The highest decline in mortality happened before 2000, with 14% in males and 11% in females.

    The most significant declines were shown in bladder, mesothelioma, and stomach malignancies in males, as well as stomach, cervical, and non-Hodgkin lymphoma in women.

    For males, the cancers with mean yearly percentage decreases in death rates of ≥1.0% per year were stomach (5.10%), mesothelioma (4.20%), bladder (3.20%), lung (3.10%), non-Hodgkin lymphoma (2.90%), testis (2.80%), Hodgkin lymphoma (2.60%), larynx (2.50%), bowel (2.50%), prostate (1.80%), myeloma (1.70%), and leukemia (1.60%).

    For females, the cancers with mean yearly reductions in death rates of ≥1.0% were of the stomach (4.20%), cervix (3.60%), non-Hodgkin lymphomas (3.20%), ovaries (2.80%), breast (2.80%), myeloma (2.30%), bowel (2.20%), mesothelioma (2.0%), laryngeal tissues (2.0%), leukemia (2.0%), bladder (1.60%), esophagus (1.20%), and kidneys (1.00%).

    In both sexes, liver (2.70%) and mouth (1.20%) malignancies had mean yearly mortality increases of ≥1.0%.

    Conclusion

    The study findings showed that cancer mortality in males and females aged 35 to 69 years decreased significantly over the last 25 years, primarily due to cancer prevention, early diagnosis, improved diagnostic testing, and successful treatment.

    However, an increase in nonsmoking risk factors may result in a rise in some malignancies. The research provides a baseline for the coming years, assessing the influence of coronavirus disease 2019 (COVID-19) on cancer incidences and outcomes.

    There are increased concerns regarding specific cancer sites, with the highest concern being the need to expedite the decline in female lung cancer.

    [ad_2]

    Source link

  • Scientists discover a key mechanism used by human herpesvirus 8 to induce cancer

    Scientists discover a key mechanism used by human herpesvirus 8 to induce cancer

    [ad_1]

    Cleveland Clinic researchers have discovered a key mechanism used by Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer. The research points to effective new treatment options for KSHV-associated cancers, including Kaposi’s sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease.

    Our findings have significant implications: viruses cause between 10% to 20% of cancers worldwide, a number that is constantly increasing as new discoveries are made. Treating virus-induced cancers with standard cancer therapies can help shrink tumors that are already there, but it doesn’t fix the underlying problem of the virus. Understanding how pathogens transform a healthy cell into a cancer cell uncovers exploitable vulnerabilities and allows us to make and repurpose existing drugs that can effectively treat virus-associated malignancies.” 


    Jun Zhao, Ph.D., Cleveland Clinic Florida Research & Innovation Center

    The Nature Communications study, led by Dr. Zhao, reveals that KSHV manipulates two human enzymes called CDK6 and CAD to reshape the way human cells produce new nucleotides – the building blocks of DNA and RNA – and process glucose. The changes to how infected cells grow and how KSHV persists put cells at a much higher risk of forming tumors and play a crucial role in causing cancer. 

    The team showed the virus activates a specific pathway driving cell metabolism and proliferation. Inhibiting this process with existing FDA-approved breast cancer drugs reduced KSHV replication, blocked lymphoma progression and shrunk existing tumors in preclinical models. 

    Like other herpesviruses, KSHV often has no symptoms initially and remains in the body after primary infection. The virus stays dormant, suppressed by the immune system. However, KSHV can reactivate when immunity is weakened – as in older people, those with HIV/AIDS, and transplant recipients. In these high-risk groups, the now active virus can trigger aggressive cancers.

    KSHV-induced cancers are fast-acting, aggressive and difficult to treat. An estimated 10% of people in North America and Northern Europe have KSHV, but this ranges throughout the globe. More than 50% of individuals in parts of Northen Africa are estimated to have the virus. Experts estimate these rates are higher, as KSHV often goes undiagnosed because of lack of symptoms. These findings have implications that reach past KSHV; researchers can apply knowledge about KSHV to other cancer-associated viruses that might use the same process to cause cancer. 

    To understand the cells’ metabolic processes to uncover the virus’s vulnerabilities, Dr. Zhao collaborated with Michaela Gack, Ph.D., Scientific Director of the Florida Research & Innovation Center. 

    Rapidly replicating cancer cells reprogram metabolism to fuel growth. Meanwhile, most viruses cannot produce energy or necessary molecules on their own, so they rely on human cells to do the work for them. The team found that the virus takes over the host protein CDK6 and CAD, causing the infected cells to produce extra metabolites, which allows faster replication of the virus and an uncontrolled proliferation of the cells.

    The research team treated pre-clinical models with a CDK6-blocking drug, Palbociclib, an FDA-approved breast cancer medication, as well as a compound targeting CAD. They saw significant decreases in tumor size and increases in cancer survival rates: most tumors virtually disappeared after about a month of treatment, and remaining tumors shrank around 80%. Survival increased to 100% for selected lymphoma cell lines. 

    Dr. Zhao and his team are working to better understand the connections among KSHV, CDK6/CAD pathway, and cancer formation. With the knowledge they obtain, they plan to implement and refine their experimental drug combinations for clinical trials. 

    “Cellular metabolism could be hijacked by both viruses and cancers for pathogenesis,” said Dr. Zhao. “By investigating these metabolic rewiring mechanisms, we aim to find the Achilles’ heel of cancer-causing viruses and non-viral cancers. I’m excited to see what the future of this work holds.” 

    Source:

    Journal reference:

    Wan, Q., et al. (2024). Hijacking of nucleotide biosynthesis and deamidation-mediated glycolysis by an oncogenic herpesvirus. Nature Communications. doi.org/10.1038/s41467-024-45852-5.

    [ad_2]

    Source link

  • Toxic gas that sterilizes medical devices prompts safety rule update

    Toxic gas that sterilizes medical devices prompts safety rule update

    [ad_1]

    Over the past two years, Madeline Beal has heard frustration and even bewilderment during public meetings about ethylene oxide, a cancer-causing gas that is used to sterilize half of the medical devices in the U.S.

    Beal, senior risk communication adviser for the Environmental Protection Agency, has fielded questions about why the agency took so long to alert people who live near facilities that emit the chemical about unusually high amounts of the carcinogenic gas in their neighborhoods. Residents asked why the EPA couldn’t close those facilities, and they wanted to know how many people had developed cancer from their exposure.

    “If you’re upset by the information you’re hearing tonight, if you’re angry, if it scares you to think about risk to your family, those are totally reasonable responses,” Beal told an audience in Laredo, Texas, in September 2022. “We think the risk levels near this facility are too high.”

    There are about 90 sterilizing plants in the U.S. that use ethylene oxide, and for decades companies used the chemical to sterilize medical products without drawing much attention. Many medical device-makers send their products to the plants to be sterilized before they are shipped, typically to medical distribution companies.

    But people living around these facilities have been jolted in recent years by a succession of warnings about cancer risk from the federal government and media reports, an awareness that has also spawned protests and lawsuits alleging medical harm.

    The EPA is expected to meet a March 1 court-ordered deadline to finalize tighter safety rules around how the toxic gas is used. The proposed changes come in the wake of a 2016 agency report that found that long-term exposure to ethylene oxide is more dangerous than was previously thought.

    But the anticipated final rules — the agency’s first regulatory update on ethylene oxide emissions in more than a decade — are expected to face pushback. Medical device-makers worry stricter regulation will increase costs and may put patients at higher risk of infection from devices, ranging from surgical kits to catheters, due to deficient sterilization. The new rules are also not likely to satisfy the concerns of environmentalists or members of the public, who already have expressed frustration about how long it took the federal government to sound the alarm.

    “We have been breathing this air for 40 years,” said Connie Waller, 70, who lives with her husband, David, 75, within two miles of such a sterilizing plant in Covington, Georgia, east of Atlanta. “The only way to stop these chemicals is to hit them in their pocketbook, to get their attention.”

    The EPA says data shows that long-term exposure to ethylene oxide can increase the risk of breast cancer and cancers of the white blood cells, such as non-Hodgkin lymphoma, myeloma, and lymphocytic leukemia. It can irritate the eyes, nose, throat, and lungs, and has been linked to damage to the brain and nervous and reproductive systems. Children are potentially more vulnerable, as are workers routinely exposed to the chemical, EPA officials say. The agency calculates the risk based on how much of the gas is in the air or near the sterilizing facility, the distance a person is from the plant, and how long the person is exposed.

    Waller said she was diagnosed with breast cancer in 2004 and that her husband was found to have non-Hodgkin lymphoma eight years later.

    A 2022 study of communities living near a sterilization facility in Laredo found the rates of acute lymphocytic leukemia and breast cancer were statistically significant, greater than expected compared with statewide rates.

    Beal, the EPA risk adviser, who regularly meets with community members, acknowledges the public’s concerns. “We don’t think it’s OK for you to be at increased risk from something that you have no control over, that’s near your house,” she said. “We are working as fast as we can to get that risk reduced with the powers that we have available to us.”

    In the meantime, local and state governments and industry groups have scrambled to defuse public outcry.

    Hundreds of personal injury cases have been filed in communities near sterilizing plants. In 2020, New Mexico’s then-attorney general filed a lawsuit against a plant in Santa Teresa, and that case is ongoing. In a case that settled last year in suburban Atlanta, a company agreed to pay $35 million to 79 people who alleged ethylene oxide used at the plant caused cancer and other injuries.

    In Cook County, Illinois, a jury in 2022 awarded $363 million to a woman who alleged exposure to ethylene oxide gas led to her breast cancer diagnosis. But, in another Illinois case, a jury ruled that the sterilizing company was not liable for a woman’s blood cancer claim.

    Greg Crist, chief advocacy officer for the Advanced Medical Technology Association, a medical device trade group that says ethylene oxide is an effective and reliable sterilant, attributes the spate of lawsuits to the litigious nature of trial attorneys.

    “If they smell blood in the water, they’ll go after it,” Crist said.

    Most states have at least one sterilizing plant. According to the EPA, a handful, like California and North Carolina, have gone further than the agency and the federal Clean Air Act to regulate ethylene oxide emissions. After a media and political firestorm raised awareness about the metro Atlanta facilities, Georgia started requiring sterilizing plants that use the gas to report all leaks.

    The proposed rules the EPA is set to finalize would set lower emissions limits for chemical plants and commercial sterilizers and increase some safety requirements for workers within these facilities. The agency is expected to set an 18-month deadline for commercial sterilizers to come into compliance with the emissions rules.

    That would help at facilities that “cut corners,” with lax pollution controls that allow emissions of the gas into nearby communities, said Richard Peltier, a professor of environmental health sciences at the University of Massachusetts-Amherst. Stronger regulation also prevents the plants from remaining under the radar. “One of the dirty secrets is that a lot of it is self-regulated or self-policed,” Peltier added.

    But the proposed rules did not include protections for workers at off-site warehouses that store sterilized products, which can continue to emit ethylene oxide. They also did not require air testing around the facilities, prompting debate about how effective they would be in protecting the health of nearby residents.

    Industry officials also don’t expect an alternative that is as broadly effective as ethylene oxide to be developed anytime soon, though they support researching other methods. Current alternatives include steam, radiation, and hydrogen peroxide vapor.

    Increasing the use of alternatives can reduce industry dependence on “the crutch of ethylene oxide,” said Darya Minovi, senior analyst with the Union of Concerned Scientists, an advocacy group.

    But meeting the new guidelines will be disruptive to the industry, Crist said. He estimates companies will spend upward of $500 million to comply with the new EPA rules and could struggle to meet the agency’s 18-month timetable. Sterilization companies will also have difficulty adjusting to new rules on how workers handle the gas without a dip in efficiency, Crist said.

    The Food and Drug Administration, which regulates drugs and medical devices, is also watching the regulatory moves closely and worries the updated emissions rule could “present some unique challenges” if implemented as proposed, said Audra Harrison, an FDA spokesperson. “The FDA is concerned about the rule’s effects on the availability of medical devices,” she added.

    Other groups, like the American Chemistry Council and the Texas Commission on Environmental Quality, the state’s environmental agency, assert that ethylene oxide use isn’t as dangerous as the EPA says. The EPA’s toxicity assessment has “severe flaws” and is “overly conservative,” the council said in an emailed statement. Texas, which has several sterilizing plants, has said ethylene oxide isn’t as high a cancer risk as the agency claims, an assessment that the EPA has rejected.

    Tracey Woodruff, a researcher at the University of California-San Francisco who previously worked at the EPA, said it can be hard for the agency to keep up with regulating chemicals like ethylene oxide because of constrained resources, the technical complications of rulemaking, and industry lobbying.

    But she’s hopeful the EPA can strike a balance between its desire to reduce exposure and the desire of the FDA not to disrupt medical device sterilization. And scrutiny can also help the device sterilization industry think outside the box.

    “We continue to discover these chemicals that we’ve already been exposed to were toxic, and we have high exposures,” she said. “Regulation is an innovation forcer.”




    Kaiser Health NewsThis article was reprinted from khn.org, a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF – the independent source for health policy research, polling, and journalism.

    [ad_2]

    Source link

  • Study reveals a crucial survival tactic employed by cancer cells

    Study reveals a crucial survival tactic employed by cancer cells

    [ad_1]

    A study led by the group of Didier Trono at EPFL has revealed a crucial survival tactic employed by cancer cells. The scientists have identified a group of proteins, known as “KRAB zinc finger proteins” (KZFPs), that help cancer cells maintain genetic stability and avoid immune system detection. The study is published in Cancer Research.

    KZFPs are like managers inside our cells, helping to control which parts of our DNA are switched on or off. For example, some KZFPs interact with transposable elements, which are repetitive DNA sequences constituting more than half of the human genome. TEs can potentially cause genetic instability if left unchecked, which makes them a threat to cell integrity and immune detection. KZFPs play a crucial role in repressing TEs, ensuring their silent state within heterochromatin, thereby safeguarding genome stability.

    The new study, led by Filipe Martins, a scientist in Trono’s group, reveals a correlation between a subset of primate-specific KZFPs and the prognosis of Diffuse Large B Cell Lymphoma. The researchers used advanced cell culture techniques, genetic manipulation via short hairpin RNAs (shRNAs), and cutting-edge genomic profiling methods to observe the effects of depleting two specific KZFPs in tumor cells from various types of cancers, including Diffuse Large B Cell Lymphoma.

    The two proteins to be depleted are known as ZNF587 and ZNF417. They were chosen because they are associated with poor prognosis in Diffuse Large B Cell Lymphoma, but they also target evolutionarily recent transposable elements, which are implicated in genomic stability and immune evasion mechanisms in cancer cells.

    Depleting ZNF587 and ZNF417 in Diffuse Large B Cell Lymphoma cells led to significant disruptions in cellular processes. The loss of these proteins resulted in the redistribution of heterochromatin, which created replicative stress, a condition where DNA replication is impeded, which can slow or stall cell division.

    This stress triggered an inflammatory response, and enhanced immune system recognition of the cancer cells – it essentially unmasked them and made them visible to the immune system. In fact, the cancer cells showed more diverse neoantigens, which leads to a heightened susceptibility to immune attacks.

    Our study shows that TE regulation and heterochromatin maintenance by KZFPs is essential also in cancer, which allowed us to uncover new functions of KZFPs, previously overlooked in cancer research due to their young evolutionary age and presumed redundancy.”


    Didier Trono at EPFL 

    He adds: “Three-quarters of KZFP genes are primate-restricted, challenging the conventional wisdom that the more conserved a protein is, the more essential it should be for cancer development. Our findings indicate that KZFPs not only regulate gene expression but also participate in DNA replication and genome stability, which can influence the genetic diversity and occurrence of subclonal populations of cancer cells, thus playing a pro-oncogenic role.”


    “This DNA damage and ‘viral mimicry’ of TEs due to their upregulation led to the activation of cell-intrinsic inflammatory pathways promoting immune rejection in vitro,” adds Filipe Martins. “These phenomena have so far been seen only with chemotherapy agents or depletion of cellular enzymes. Therefore, targeting transcription factors holds the promise of a potential immunogenic chemotherapy-like effect.”

    The findings suggest that cancer cells may exploit these proteins to temper their visibility to immune surveillance. “It is a true conceptual breakthrough,” says Trono. “Transposable elements, which most consider only as genetic threats, were revealed to be sentinels against loss of epigenetic controls, and their KZFPs regulators were shown to be subverted by cancer cells to escape this surveillance.”

    The findings also highlight potential new targets for therapy of Diffuse Large B Cell Lymphoma. “The discovery points immediately to novel therapeutic avenues for this disease,” says Trono. “It is a line of research for which we are currently raising funds for a large consortium comprising several groups from EPFL in addition to others from Stanford, the Curie Institute, Cornell, the van Andel Institute and London’s Bart Institute, and we are also working towards the launching of a startup.”

    Source:

    Journal reference:

    Martins, F., et al. (2024) A cluster of evolutionarily recent KRAB zinc finger proteins protects cancer cells from replicative stress-induced immunogenic inflammation. Cancer Research. doi.org/10.1158/0008-5472.CAN-23-1237.

    [ad_2]

    Source link

  • New immunotherapy borrows cancer’s tricks to unleash powerful T cells

    New immunotherapy borrows cancer’s tricks to unleash powerful T cells

    [ad_1]

    Immunotherapies using engineered T cells have ushered in a new era in cancer treatment, but they have their limits. They may cause side effects or stop working, and they do not work at all against 90% of cancers. 

    Now, scientists at UC San Francisco and Northwestern Medicine may have found a way around these limitations by borrowing a few tricks from cancer itself. 

    By studying mutations in malignant T cells that cause lymphoma, they zeroed in on one that imparted exceptional potentcy to engineered T cells. The team inserted a gene for this unique mutation into normal human T cells, which made them more than 100 times more potent at killing cancer cells. They kept the tumors at bay for many months, showing no signs of becoming toxic.

    While current immunotherapies work only against cancers of the blood and bone marrow, the new approach was able to kill solid tumors derived from skin, lung and stomach tissues in mice. The team has already begun working toward testing this new approach in people.

    The breakthrough was inspired by the martial arts principle of using an opponent’s strength against them, said Kole Roybal, PhD, a co-author of the study and associate professor in microbiology and immunology. 

    We’ve used the mutations that give cancer cells their staying power to engineer what we call a ‘Judo T-cell therapy’ that can survive and thrive in the harsh conditions that tumors create.” 


    Kole Roybal, PhD, co-author of the study and associate professor in microbiology and immunology

    The study appears Feb. 7 in Nature

    A solution hiding in plain sight

    Immunology has proved difficult against most cancers because a solid tumor creates an environment focused on sustaining itself, redirecting resources like oxygen and nutrients for its own benefit. Often, cancerous tumors hijack the body’s immune system, causing it to defend, rather than attack, the cancer. 

    Not only does this impair the ability of regular T cells to target cancer cells, it also undermines the effectiveness of engineered T cells that are used in immunotherapies, which quickly tire against the tumor’s defenses. For immunotherapy treatments to work under those conditions, “We need to give healthy T cells abilities that are beyond what they can naturally achieve,” said Roybal, who is also a member of the Gladstone Institute of Genomic Immunology. 

    Using such T cells from patients with lymphoma, the UCSF and Northwestern teams screened 71 mutations, eventually isolating one that proved both potent and non-toxic, subjecting it to a rigorous set of safety tests.

    “This approach performs better than anything we’ve seen before,” said Jaehyuk Choi, MD, PhD, an associate professor of medical dermatology, as well as biochemistry and molecular genetics, at Northwestern University Feinberg School of Medicine. 

    “Our discoveries empower T cells to kill multiple cancer types and have the potential to offer cures to people who have a poor prognosis,” he said, noting that because cell therapies live and grow inside the patient, they can provide long-term immunity against cancer.

    In collaboration with the Parker Institute for Cancer Immunotherapy and venture capital firm Venrock, Roybal and Choi have launched a new company, Moonlight Bio, to realize the potential of their “judo” approach. Their first project is developing a lung cancer therapy that they hope to begin testing in people within the next few years.

    “We see this as the starting point,” Roybal said. “There’s so much to learn from nature about how we can enhance these cells and tailor them to different types of diseases.”

    Source:

    Journal reference:

    Garcia, J., et al. (2024). Naturally occurring T cell mutations enhance engineered T cell therapies. Nature. doi.org/10.1038/s41586-024-07018-7.

    [ad_2]

    Source link